<?xml version="1.0" encoding="UTF-8"?>
<ref id="R24">
 <label>24</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Colston</surname>
    <given-names>E</given-names>
   </name>, 
   <name name-style="western">
    <surname>Grasela</surname>
    <given-names>D</given-names>
   </name>, 
   <name name-style="western">
    <surname>Gardiner</surname>
    <given-names>D</given-names>
   </name>, 
   <etal>et al</etal>
  </person-group>
  <article-title>An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients</article-title>. 
  <source>PLoS One</source>
  <year>2018</year>;
  <volume>13</volume>:
  <elocation-id>e0198158</elocation-id>. 
  <pub-id pub-id-type="doi">10.1371/journal.pone.0198158</pub-id>
  <?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/29879143?>
  <pub-id pub-id-type="pmid">29879143</pub-id>
 </mixed-citation>
</ref>
